Second-Line and Subsequent Therapies after Atezolizumab Plus Bevacizumab Treatment in Hepatocellular Carcinoma: A Multicenter Prospective Cohort Study

Background/Aims : Optimal second-line (2L) and third-line (3L) systemic therapies after first-line (1L) atezolizumab plus bevacizumab (AtezoBev) for advanced hepatocellular carcinoma (HCC) remain undefined. This prospective multicenter study evaluated the efficacy and safety of various 2L and 3L sys...

Descrizione completa

Dettagli Bibliografici

Autori principali:	Yuri Cho, Jeong-Hoon Lee, Baek-Yeol Ryoo, Ho Yeong Lim, Dong Eun Lee, Bo Hyun Kim, Joong-Won Park
Natura:	Artigo
Lingua:	Inglês
Pubblicazione:	Gastroenterology Council for Gut and Liver 2026-07-01
Serie:	Gut and Liver
Soggetti:	hepatocellular carcinoma atezolizumab plus bevacizumab second-line treatment lenvatinib sorafenib
Accesso online:	http://gutnliver.org/journal/view.html?doi=10.5009/gnl250532
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!